BioWorld Asia

April 1, 2009

Intercell Gets Stock Boost as FDA Approves Ixiaro

Shares in Intercell AG received a significant boost Tuesday on news that the FDA approved its Japanese Encephalitis Virus (JEV) vaccine Ixiaro late Monday. (BioWorld International) Read More

BioVex Raises $40M to Fund Melanoma Vaccine Study

More Breast Cancer Genes to Boost Genetic Screening

EU Animal Directive Draws Ire from UK Researchers

Survey Points to Trouble Raising Funds in the UK

TcLand, Genedata Collaborate on Autoimmune Biomarkers

Newron Moves Ralfinamide into Pivotal Pain Trials

Other News To Note

Today's news in brief

BioWorld

BioWorld briefs for July 21, 2026.

ALN-5288 lowers tau levels in preclinical models

BioWorld Science

Pathological tau accumulation is a key driver of neurodegeneration in Alzheimer’s disease (AD) and other tauopathies such as progressive supranuclear palsy....

LIT-002 is strong candidate for autism and neuropathic pain

BioWorld Science

Researchers from the University of Strasbourg and the Centre National de la Recherche Scientifique (CNRS) have presented data on LIT-002, a nonpeptide oxytocin...

News in brief

BioWorld Asia

BioWorld Asia briefs for July 21, 2026

New biomarker may improve RSV drug screening

BioWorld

Respiratory syncytial virus (RSV) infection is responsible for 3.2 million hospital admissions and about 118,000 deaths in children under 5 years of age. The...